Zacks Investment Research on MSN10h
Elevation Oncology Plunges 42% on Ending Development of Lead DrugShares of Elevation Oncology ELEV plunged more than 40% yesterday after reporting disappointing data from a phase I study on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback